$15.52
1.24% yesterday
Nasdaq, Sep 27, 10:01 pm CET
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Inhibrx Inc Stock price

$15.52
+1.33 9.37% 1M
-15.54 50.04% 6M
-18.06 53.79% YTD
-2.08 11.84% 1Y
-16.53 51.57% 3Y
-2.71 14.87% 5Y
-2.71 14.87% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.19 1.24%
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Key metrics

Market capitalization $221.92m
Enterprise Value $180.33m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 101.31
P/S ratio (TTM) P/S ratio 124.67
P/B ratio (TTM) P/B ratio 1.01
Revenue growth (TTM) Revenue growth 39.30%
Revenue (TTM) Revenue $1.78m
EBIT (operating result TTM) EBIT $-249.28m
Free Cash Flow (TTM) Free Cash Flow $-222.10m
Cash position $226.86m
EPS (TTM) EPS $-5.35
P/E forward 0.18
P/S forward 554.80
EV/Sales forward 450.83
Short interest 5.71%
Show more

Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Inhibrx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Inhibrx Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Inhibrx Inc forecast:

Buy
33%
Hold
67%

Financial data from Inhibrx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
1.78 1.78
39% 39%
100%
- Direct Costs 1.69 1.69
41% 41%
95%
0.09 0.09
106% 106%
5%
- Selling and Administrative Expenses - -
- Research and Development Expense 217 217
78% 78%
12,196%
-248 -248
76% 76%
-13,910%
- Depreciation and Amortization 1.69 1.69
41% 41%
95%
EBIT (Operating Income) EBIT -249 -249
73% 73%
-14,004%
Net Profit -271 -271
66% 66%
-15,234%

In millions USD.

Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibrx Inc Stock News

Neutral
InvestorPlace
about one month ago
Inhibrx (NASDAQ: INBX ) just reported results for the first quarter of 2024. Inhibrx reported earnings per share of -$1.44.
Neutral
PRNewsWire
about 2 months ago
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 202...
Positive
Seeking Alpha
4 months ago
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
More Inhibrx Inc News

Company Profile

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Head office United States
CEO Mark Lappe
Founded 2010
Website www.inhibrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today